News
DTCFF
0.410
NaN%
--
Weekly Report: what happened at DTCFF last week (0413-0417)?
Weekly Report · 2h ago
Weekly Report: what happened at DTCFF last week (0406-0410)?
Weekly Report · 04/13 10:45
Weekly Report: what happened at DTCFF last week (0330-0403)?
Weekly Report · 04/06 10:45
Weekly Report: what happened at DTCFF last week (0323-0327)?
Weekly Report · 03/30 10:45
Weekly Report: what happened at DTCFF last week (0316-0320)?
Weekly Report · 03/23 10:41
Defence Therapeutics Eases Terms on 800,000 Warrants to Boost Investor Uptake
TipRanks · 03/21 03:42
Defence Therapeutics reprices 800,000 warrants to CAD 0.75
Reuters · 03/20 22:01
Defence Therapeutics Announces Warrant Terms Amendment
Newsfile · 03/20 22:00
Weekly Report: what happened at DTCFF last week (0309-0313)?
Weekly Report · 03/16 10:40
Defence Therapeutics Raises $9.6 Million in Private Placement to Advance Oncology Programs
TipRanks · 03/09 12:00
Weekly Report: what happened at DTCFF last week (0302-0306)?
Weekly Report · 03/09 10:40
Defence Therapeutics Closes $9.6M Private Placement of Units
Reuters · 03/09 07:16
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Newsfile · 03/09 07:15
Defence Therapeutics Targets Global Partnerships as It Showcases Accum Platform at March Industry Events
TipRanks · 03/02 15:21
Weekly Report: what happened at DTCFF last week (0223-0227)?
Weekly Report · 03/02 10:39
Defence Therapeutics to Attend BIO-Europe Spring in Lisbon
Reuters · 03/02 08:16
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Newsfile · 03/02 08:15
Defence Therapeutics Seeks Up to $11 Million in Structured Private Placement
TipRanks · 02/28 00:09
Defence Therapeutics to raise up to $11 million in private placement
Seeking Alpha · 02/27 22:10
Defence Therapeutics launches up to $11 million private placement of units
Reuters · 02/27 22:01
More
Webull provides a variety of real-time DTCFF stock news. You can receive the latest news about Defence Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About DTCFF
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.